I Want To...
I Want To...
Find Research Faculty
Enter the last name, specialty or keyword for your search below.
School of Medicine
I Want to...
Kelly Elise Dooley, M.D., M.P.H., Ph.D.
Associate Professor of Medicine
Languages: English, French
Expertise: Infectious Disease
Research Interests: Evaluation of new drug regimens for the treatment of tuberculosis and co-treatment of TB and HIV; Clinical pharmacology of anti-infective agents ...read more
Request an Appointment
I live in Maryland
Request an appointment through My
I live outside of Maryland
I live outside of the United States
Dr. Kelly Dooley is an associate professor of medicine at the Johns Hopkins University School of Medicine. She also holds an appointment in pharmacology and molecular sciences. Her areas of clinical expertise include infectious disease.
Dr. Dooley earned her M.D. from Duke University and her Ph.D. from the Johns Hopkins Bloomberg School of Public Health. She completed her residency and performed a fellowship in infectious diseases at Johns Hopkins.
She has an HIV outpatient practice and attends on the inpatient HIV service. Her research focuses on tuberculosis therapeutics, with an emphasis on Phase I or II clinical trials of new or existing TB drugs and treatment of HIV/TB co-infection. She is principal investigator or protocol chair for several clinical trials involving TB drugs for drug-sensitive TB or drug-resistant TB. She’s also involved in the scientific committees of the Tuberculosis Trials Consortium, AIDS Clinical Trials Group and IMPAACT networks. She has a special interest in optimizing TB drugs for special populations, including children and pregnant women.
Dr. Dooley serves as a firm faculty leader for the Osler Medical Housestaff Training Program.
- Associate Professor of Medicine
- Associate Professor of Pharmacology and Molecular Sciences
Departments / Divisions
- MD, Duke University School of Medicine (1999)
- Johns Hopkins University School of Medicine / Internal Medicine (2002)
- Johns Hopkins University School of Medicine / Infectious Diseases (2009)
- American Board of Internal Medicine / Internal Medicine (2002)
Research & Publications
Dr. Dooley’s research focuses on clinical pharmacology of new anti-tuberculosis regimens with an emphasis on: (1) Phase I clinical trials of new or existing anti-TB drugs, including dose escalation trials and studies of drug-drug interactions between anti-TB agents and antiretrovirals to treat HIV; (2) Use of PK/PD analysis and modelling in Phase II tuberculosis clinical treatment trials to determine concentration-effect relationships that will allow for optimization of dosing; (3) Evaluation of TB and HIV drug concentrations in special populations, such as pregnant women and children; (4) Evaluation of treatment-shortening regimens for drug-sensitive TB and investigational regimens for treatment of multidrug-resistant TB; and (5) Translational work involving novel animal models of cavitary pulmonary TB disease to understand drug distribution in diseased lung.
Lab Website: Kelly E. Dooley Laboratory
Selected PublicationsView all on Pubmed
Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. "Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis." Antimicrob Agents Chemother. 2013 Jun;57(6):2780-7. doi: 10.1128/AAC.00191-13. Epub 2013 Apr 9.
Svensson EM, Dooley KE, Karlsson MO. "Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection." Antimicrob Agents Chemother. 2014 Nov;58(11):6406-12. doi: 10.1128/AAC.03246-14. Epub 2014 Aug 11.
Svensson EM, Murray S, Karlsson MO, Dooley KE. "Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug." J Antimicrob Chemother. 2015 Apr;70(4):1106-14. doi: 10.1093/jac/dku504. Epub 2014 Dec 21.
Dooley KE, Park JG, Swindells S, Allen R, Haas DW, Cramer Y, Aweeka F, Wiggins I, Gupta A, Lizak P, Qasba S, van Heeswijk R, Flexner C; ACTG 5267 Study Team. "Safety, tolerability, and pharmacokinetic interactions of the antituberculous agent TMC207 (bedaquiline) with efavirenz in healthy volunteers: AIDS Clinical Trials Group Study A5267." J Acquir Immune Defic Syndr. 2012 Apr 15;59(5):455-62. doi: 10.1097/QAI.0b013e3182410503.
Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; the TSHEPISO Study Team. Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis co-infection. J Infect Dis. 2014 Jul 31. pii: jiu429. [Epub ahead of print] PMID: 25081933
Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS Clinical Trials Group (ACTG) A5306 Study Team. Phase I Safety, Pharmacokinetics, and Pharmacogenetics Study of the Anti-Tuberculosis Drug PA-824 with Concomitant Lopinavir/Ritonavir, Efavirenz, or Rifampin. Antimicrob Agents Chemother. 2014 Jun 23. pii: AAC.03332-14. [Epub ahead of print] PMID: 24957823
Savic RM, Lu Y, Bliven-Sizemore E, Weiner M, Nuermberger E, Burman W, Dorman SE, Dooley KE. Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability. Antimicrob Agents Chemother. 2014 Jun;58(6):3035-42. doi: 10.1128/AAC.01918-13. Epub 2014 Mar 10. PMID: 24614383 [PubMed - in process]
Cherkaoui I, Sabouni R, Ghali I, Kizub D, Billioux AC, Bennani K, Bourkadi JE, Benmamoun A, Lahlou O, Aouad RE, Dooley KE. Treatment default amongst patients with tuberculosis in urban Morocco: predicting and explaining default and post-default sputum smear and drug susceptibility results. PLoS One. 2014 Apr 3;9(4):e93574. doi: 10.1371/journal.pone.0093574. eCollection 2014. PMID: 24699682 [PubMed - in process]
Williamson B, Dooley KE, Zhang Y, Back DJ, Owen A. Induction of influx and efflux transporters and cytochrome P450 3A4 in primary human hepatocytes by rifampin, rifabutin, and rifapentine. Antimicrob Agents Chemother. 2013 Dec;57(12):6366-9. doi: 10.1128/AAC.01124-13. Epub 2013 Sep 23. PMID: 24060875
Academic Affiliations & Courses
Graduate Program Affiliation
Activities & Honors
- Firm Faculty Leader (Janeway Firm), Osler Medical Housestaff Training Program, Johns Hopkins, Baltimore, MD
- Task Force on Women's Academic Careers in Medicine, Johns Hopkins Department of Medicine, Baltimore, MD, 2012